Notice of Extraordinary Annual Meeting July 11th 2016
June 27th 2016 Notice of Annual Meeting July 11th 2016. The Annual Meeting 2016 will tale place at the Companys site Nycovn. 2, Oslo from 3 pm to 5 pm.
Protocol from Annual Meeting June 22nd 2016
June 22nd 2016 Protocol from Annual Meeting June 22nd 2016
Regenics AS Annual Report 2016
Regenics post a positive 2016 result with topline of 0.35 mill NOK. 
Graduate students summer 2016
Regenics welcomes 2 summer students for intership
Vernex™ clinical study approved by REK
REK the Regional Ethics Commitee of Norway has approved REG 002 a clincial safety study in humans. 
Notice of Annual Meeting June 22nd 2016
June 8th 2016 Notice of Annual Meeting June 22nd 2016. The Annual Meeting 2016 will take place in the Companys office, Nycovn. 2, Oslo at 3 pm to 5 pm. 
Regenics signs CE marking consultancy agreement with Haflan Resources AS
Regenics AS signs on EU medical device consultancy agreement with Haflan Resources AS.
In-cosmetics Paris 2016
Traditionally, as every year, Regenics took a part in the largest cosmetics fairs, placed this year in France. On 12-14th April, in-cosmetics Global 2016 returned to Paris and in its...
Innovation Norway grants loan to Regenics
Regenics is granted Innovation Norway loan of 2.5 mill NOK.
EPO patent granted
Regenics is pleased to announce the granting of EPO (European Patent Office) patent on its core technology on March 28th 2016 
AquaDerma wins Norwegian cosmetic award 2016
AquaDerma, the new LEX® containing cosmetic series from Orkla Lilleborg wins Norwegian Cosmetics Award 2016. 
Eurostars consortium established
Eurostars consortium established by Regenics AS, Norway
DnB Healthcare conference 2015
Regenics AS presents at the DnB Healtcare conference 2015, Venture session, December 15th 2015, session 5 at 15:39 Welcome!
In-cosmetics Bangkok 2015
In Cosmetics, 2015, Bangkok  
Publication: Reepitelialization of burn wounds ETRS-WHS
Regenics today annonces a positive result for its wound healing technology using salmon roe extracts to treat 2nd degree burn wounds in human skin
Asia and Australia Distributors for LEX®
Regenics AS has signed non-exclusive test sale agreements for LEX® with selected cosmetic ingredient distributors for China, Taiwan, Korea and Australia.  
Regenics Joins Oslo Cancer Cluster
Regenics was May 18th invited as a member  of Oslo Cancer Cluster NCE (Norwegian Centre for Expertise). 
Publication: Medibiome AB preliminary report
Medibiome AB issues today a preliminary report of first results of Vernex™ exposure to human skin explants showing improved and faster reepitelialization of seconday degree induced burn wounds over placebo.
In-cosmetics Barcelona 2015
Regenics visited in-cosmetics in Spain, which held on 14-16th April. Participation in the largest cosmetics fairs in Europe was for Regenics great opportunity to meet with current customers and establish...
BIA 2015 grant to Regenics AS
Regenics receieves 2015-2018 R&D grant from Norwegian Research Council in the BIA (brukerstyrt innovasjonsarena) programme.
Regenics AS Annual Report 2014
Regenics AS Annual Report 2014
2015 Eurostars funding to Regenics
Regenics is awarded Eurostars R&D funding for Vernex® wound healing device development.
Medibiome AB collaboration
Medibiome AB, Sweden and Regenics AS Oslo agrees collaboration on evaluation of Vernex™ in human skin explant model.
Orkla-Lilleborg launches AquaDerma
Lilleborg launches AquaDerma - a new, LEX® containing cosmetic series in Norway.

<<  <   Page 4 of 5   >  >>

Regenics AS has developed a number of assays and techniques to study effects of various substances on skin cells both in vitroin vivo and in the clinic. Our focus is to develop products and techniques for therapeutic skin applications and to improve skin appearance.